South Dakota Investment Council Has $17.61 Million Position in Solventum Co. (NYSE:SOLV)

South Dakota Investment Council lowered its stake in shares of Solventum Co. (NYSE:SOLV) by 1.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 266,579 shares of the company’s stock after selling 3,400 shares during the quarter. South Dakota Investment Council owned about 0.15% of Solventum worth $17,610,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Worldquant Millennium Advisors LLC grew its position in Solventum by 373.6% during the third quarter. Worldquant Millennium Advisors LLC now owns 47,665 shares of the company’s stock worth $3,323,000 after buying an additional 37,600 shares in the last quarter. Harbor Capital Advisors Inc. boosted its holdings in shares of Solventum by 24.8% in the 4th quarter. Harbor Capital Advisors Inc. now owns 46,965 shares of the company’s stock valued at $3,103,000 after purchasing an additional 9,333 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in shares of Solventum by 37.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 117,853 shares of the company’s stock valued at $8,217,000 after purchasing an additional 32,051 shares in the last quarter. State Street Corp boosted its holdings in shares of Solventum by 3.1% in the 3rd quarter. State Street Corp now owns 6,107,550 shares of the company’s stock valued at $425,818,000 after purchasing an additional 185,938 shares in the last quarter. Finally, Forsta AP Fonden acquired a new stake in shares of Solventum during the 4th quarter valued at $1,876,000.

Solventum Stock Down 1.9 %

SOLV stock opened at $73.08 on Friday. The stock has a 50-day moving average price of $71.14 and a 200-day moving average price of $69.15. Solventum Co. has a 1-year low of $47.16 and a 1-year high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analyst Ratings Changes

Several equities research analysts recently weighed in on SOLV shares. Mizuho started coverage on Solventum in a report on Wednesday, December 4th. They set a “neutral” rating and a $70.00 price objective on the stock. Piper Sandler raised their price objective on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a report on Friday, November 8th. Finally, Morgan Stanley raised their price objective on Solventum from $60.00 to $73.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating and one has issued a buy rating to the company’s stock. According to data from MarketBeat.com, Solventum has an average rating of “Hold” and an average price target of $68.29.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.